(TRIAL ONGOING) This clinical trial, that commenced on 14 April 2020, is trialling HBOT-treatment for 100 COVID-19 positive patients who are oxygen-dependent with hypoxemic pneumonia. Participants are randomized into HBOT treatment group vs non-HBOT control group. During the current one month duration trial, the HBOT treatment group are receiving one session per day of HBOT. Both groups are receiving same inpatient standard treatment of normobaric oxygen. Specific study endpoints are being compared between the two group, including time to normalize oxygen requirement (oxygen-dependence), days of hospitalization, oxygen flow values by pulse oximetry, days on invasive mechanical ventilation and mortality statistics.